Everything below concerns human growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Rehabilitation and exercise === Cardiac rehabilitation benefits many who have experienced myocardial infarction, even if there has been substantial heart damage and resultant left ventricular failure. It should start soon after discharge from the hospital. The program may include lifestyle advice, exercise, social support, as well as recommendations about driving, flying, sports participation, stress management, and sexual intercourse. Returning to sexual activity after myocardial infarction is a major concern for most patients, and is an important area to be discussed in the provision of holistic care. In the short-term, exercise-based cardiovascular rehabilitation programs may reduce the risk of a myocardial infarction, reduces a large number of hospitalizations from all causes, reduces hospital costs, improves health-related quality of life, and has a small effect on all-cause mortality. Longer-term studies indicate that exercise-based cardiovascular rehabilitation programs may reduce cardiovascular mortality and myocardial infarction.
Shikimate Dehydrogenase catalyzes the reversible NADPH-dependent reaction of 3-dehydroshikimate to shikimate. The enzyme reduces the carbon-oxygen double bond of a carbonyl functional group to a hydroxyl (OH) group, producing the shikimate anion. The reaction is NADPH dependent with NADPH being oxidised to NADP+.
Green nanotechnology refers to the use of nanotechnology to enhance the environmental sustainability of processes producing negative externalities. It also refers to the use of the products of nanotechnology to enhance sustainability. It includes making green nano-products and using nano-products in support of sustainability. The word GREEN in the name Green Nanotechnology has dual meaning. On one hand it describes the environment friendly technologies utilized to synthesize particles in nano scale; on the other hand it refers to the nanoparticles synthesis mediated by extracts of chlorophyllus plants. Green nanotechnology has been described as the development of clean technologies, "to minimize potential environmental and human health risks associated with the manufacture and use of nanotechnology products. It also encourages replacement of existing products with new nano-products that are more environmentally friendly throughout their lifecycle."
6 February – Former Chancellor of the Exchequer Kwasi Kwarteng announced he is stepping down from Parliament at the next election. The UK government gives Birmingham City Council to go-ahead to increase its Council Tax by 10% from April. Welsh Government minister Hannah Blythyn announces that the Welsh Government is taking over South Wales Fire and Rescue Service after it was found to have a culture of harassment and misogynism. Elena Whitham resigns from the post of Minister for Drugs and Alcohol Policy for health reasons. Former prime minister Liz Truss launches a campaign to "galvanise" the UK's "secret Conservatives" and fight back against the "left wing extremists" she says have taken over the UK's institutions. 7 February – Sunak faced a call from a Labour MP to apologise after he ridiculed Starmer over his U-turn on "defining a woman" at Prime Minister's Questions. Met Office data obtained by BBC Verify raises questions over UK government suggestions that poor weather conditions had no impact on a fall in English Channel migrant crossings during 2023. The number of crossings were fewer than during the previous year, which the government had said was nothing to do with the weather, but the figures suggest there were fewer days during 2023 when compared to 2022 when migrants could successfully cross the Channel. 8 February – Labour scraps its plans for a £28bn annual green investment, with Sir Keir Starmer saying the policy is unaffordable because of the Conservatives' economic record.
The diagnosis of MADD needs to be considered in patients who have exercise induced myalgia, cramps and sometimes weakness. A mildly elevated creatine kinase may also occur. Exclusion of other muscular diseases such as McArdle's Disease and carnitine cycle abnormalities should occur. MADD may be identified if there is a lack of ammonia rise after forearm exercise testing. The diagnosis may then be confirmed with genetic testing.
Sources: en.wikipedia.org
"A/B testing" is a shorthand for a simple randomized controlled experiment, in which a number of samples (e.g. A and B) of a single vector-variable are compared. A/B tests are widely considered the simplest form of controlled experiment, especially when they only involve two variants. However, by adding more variants to the test, its complexity grows. The following example illustrates an A/B test with a single variable: A company has a customer database of 2,000 people and launches an email campaign with a discount code in order to generate sales through its website. The company creates two versions of the email with different calls to action (the part of the copy that encourages customers to act—in the case of a sales campaign, make a purchase) and identifying promotional codes.
Among the actinides, thorium and uranium are the easiest to isolate. Thorium is extracted mostly from monazite: thorium pyrophosphate (ThP2O7) is reacted with nitric acid, and the produced thorium nitrate treated with tributyl phosphate. Rare-earth impurities are separated by increasing the pH in sulfate solution. In another extraction method, monazite is decomposed with a 45% aqueous solution of sodium hydroxide at 140 °C. Mixed metal hydroxides are extracted first, filtered at 80 °C, washed with water and dissolved with concentrated hydrochloric acid. Next, the acidic solution is neutralized with hydroxides to pH = 5.8 that results in precipitation of thorium hydroxide (Th(OH)4) contaminated with ~3% of rare-earth hydroxides; the rest of rare-earth hydroxides remains in solution. Thorium hydroxide is dissolved in an inorganic acid and then purified from the rare earth elements. An efficient method is the dissolution of thorium hydroxide in nitric acid, because the resulting solution can be purified by extraction with organic solvents:
=== Antagonists === Non-selective Caffeine Theophylline CGS-15943 Selective 8-Cyclopentyl-1,3-dimethylxanthine (CPX / 8-cyclopentyltheophylline) 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) 8-Phenyl-1,3-dipropylxanthine Bamifylline BG-9719 Tonapofylline (BG-9928) FK-453 FK-838 Rolofylline (KW-3902) N-0861 ISAM-CV202
==== First CONMEBOL and regional tournaments (1945–1946) ==== Colombia made their Copa América debut at the 1945 tournament in Chile, their first appearance in an official CONMEBOL competition. With no professional league or national selection system in place, the squad was built almost entirely around Junior de Barranquilla, then one of the strongest amateur sides on the Caribbean coast, and every player was registered simply as an amateur. Roberto Meléndez acted as player-manager, appearing on the wing while also selecting the side. Drawn against Brazil, Uruguay, Argentina, Chile, Ecuador and Bolivia, Colombia lost their first four matches but finished with a 3–1 win over Ecuador and a 3–3 draw with Bolivia to place fifth of seven.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.